Scaling AI-Driven Research in Life Sciences
BMS Deploys NVIDIA Systems for Powerful AI Drug Factory
Bristol Myers Squibb aims to scale research in oncology and neuroscience using NVIDIA's Vera Rubin architecture.
A futuristic pharmaceutical lab setting with rows of advanced server racks and holographic data visualizations representing drug discovery and AI research.
Photo: Avantgarde News
Bristol Myers Squibb (BMS) announced the deployment of NVIDIA DGX Vera Rubin NVL72 systems to create a dedicated AI factory [1]. This infrastructure is expected to be the most powerful AI setup in the life sciences sector [1][2]. The initiative aims to accelerate drug discovery and development across key therapeutic areas including oncology, hematology, and neuroscience [1].
The company plans to use this advanced computing power to scale AI-driven research models [1]. By integrating these high-performance systems, BMS seeks to improve the efficiency of identifying new drug candidates [2]. This move positions BMS as a leader in computational biology, competing with similar AI investments from rivals like Eli Lilly and Roche [3].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
blogs.nvidia.com
https://blogs.nvidia.com/blog/bristol-myers-squibb-building-life-science-industrys-most-advanced-ai-factory-on-nvidia-vera-rubin/
- 2.↗
fiercebiotech.com
https://www.fiercebiotech.com/biotech/bms-expands-ai-footprint-nvidia-create-largest-drug-rd-supercomputer
- 3.↗
drugdiscoverytrends.com
https://www.drugdiscoverytrends.com/bms-claims-pharmas-most-powerful-ai-supercomputer-how-it-stacks-up-to-lillys-and-roches/
Related stories
View all
Topics
About the author
Avantgarde News Desk covers scaling ai-driven research in life sciences and editorial analysis for Avantgarde News.